Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China

Abstract

Background and aims: Clinical data regarding patients with chronic hepatitis B (CHB) after Omicron BA.5 infection are currently limited. This study aimed to assess the clinical characteristics of patients with CHB and Omicron BA.5 infection in South China.

Methods:This retrospective study was conducted from January to March 2023 in a cohort of 485 healthy individuals and 553 patients with CHB. Clinical features, encompassing COVID-19-related symptoms, levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, vaccination status, liver functions, and virological markers of hepatitis B virus (HBV) infection were measured.

Results: COVID-19-related symptom patterns were similar in both groups, except for fever, which was notably less prevalent (85.4% vs. 90.4%, P = 0.047) among patients with CHB who experienced a significantly shorter duration of fever (median 2.2 (25th-75th percentile, 1.0-3.0) days vs. 2.3 (1.0-3.0) days, P = 0.048) and a shorter time for symptom relief (9.2 (5.0-14.0) vs. 11.1 (5.0-14.0) days, P = 0.015). The levels of SARS-CoV-2 antibodies were comparable between the two groups but increased after booster vaccinations. In patients with CHB, globulin (GLB) and hepatitis B envelope antibody levels were significantly increased after Omicron BA.5 infection, regardless of nucleos(t)ide analog regimens comparing entecavir (ETV) with tenofovir (TFV). Patients with CHB treated with TFV had significantly higher levels of SARS-CoV-2 antibodies than those treated with ETV (1065.1 (346.9-1188.5) COI vs. 765.5 (24.5-1119.1) COI, P = 0.025).

Conclusions: No significant exacerbation of COVID-19 symptoms was observed in conjunction with the efficacy of COVID-19 booster vaccinations. There were no notable alterations in liver functions except for GLB. HBV reactivation, as evidenced by increased HBV DNA, was observed among patients with CHB after Omicron BA.5 infection. These changes were not affected by ETV versus TFV administration; however, TFV resulted in a significant increase in SARS-CoV-2 antibody levels. Further studies are required to improve care and therapeutics for patients with CHB who contracted COVID-19.

Keywords

Hepatitis B virus (HBV) / Coronavirus disease 2019 (COVID-19) / Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) / Omicron / BA.5 / Entecavir (ETV) / Tenofovir (TFV)

References

[1] Lazarus JV, Block T, Bréchot C, et al. The hepatitis B epidemic and the urgent need for cure preparedness. Nat Rev Gastroenterol Hepatol. 2018;15:517-518. https://doi.org/10.1038/s41575-018-0041-6.

[2] Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97:230-238. https://doi.org/10.2471/BLT.18.219469.

[3] Peng W, Gu H, Cheng D, et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Front Microbiol. 2023;14:1185492. https://doi.org/10.3389/fmicb.2023.1185492.

[4] Dave S, Park S, Murad MH, et al. Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology. 2021;73: 68-78. https://doi.org/10.1002/hep.31267.

[5] Fauci AS, Lane HC, Redfield RR. Covid-19-navigating the uncharted. N Engl J Med. 2020;382:1268-1269. https://doi.org/10.1056/NEJMe2002387.

[6] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and chal-lenges. Lancet Gastroenterol Hepatol. 2020;5:428-430. https://doi.org/10.1016/S2468-1253(20)30057-1.

[7] Oh IS, Park SH. Immune-mediated liver injury in hepatitis B virus infection. Immune Netw. 2015;15:191-198. https://doi.org/10.4110/in.2015.15.4.191.

[8] Sagnelli C, Montella L, Grimaldi P, et al. COVID-19 as another trigger for HBV reactivation: clinical case and review of literature. Pathogens. 2022;11:816. https://doi.org/10.3390/pathogens11070816.

[9] Yang S, Wang S, Du M, Liu M, Liu Y, He Y. Patients with COVID-19 and HBV coinfection are at risk of poor prognosis. Infect Dis Ther. 2022;11:1229-1242. https://doi.org/10.1007/s40121-022-00638-4.

[10] Zhu JH, Peltekian KM. HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis. Can Liver J. 2021;4:16-22. https://doi.org/10.3138/canlivj-2020-0029.

[11] Liu R, Zhao L, Cheng X, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2021;41:720-730. https://doi.org/10.1111/liv.14774.

[12] Tallei TE, Alhumaid S, AlMusa Z, et al. Update on the omicron sub-variants BA.4 and BA.5. Rev Med Virol. 2023;33:e2391. https://doi.org/10.1002/rmv.2391.

[13] Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022;7:151. https://doi.org/10.1038/s41392-022-01009-8.

[14] Knezevic I, Mattiuzzo G, Page M, et al. WHO International Standard for eval-uation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3:e235ee240. https://doi.org/10.1016/S2666-5247(21)00266-4.

[15] Bai F, Tomasoni D, Falcinella C, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28:e9-611.e16. https://doi.org/10.1016/j.cmi.2021.11.002.

[16] Feng H, Gan CCR, Leiva D, Zhang BL, Davies SE. COVID-19, sex, and gender in China: a scoping review. Global Health. 2022;18:9. https://doi.org/10.1186/s12992-022-00804-w.

[17] Chen Z, Huang T, He T, et al. Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study. J Med Virol. 2023;95:e28695. https://doi.org/10.1002/jmv.28695.

[18] Wang J, Lu Z, Jin M, et al. Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study. Front Med. 2022;16:111-125. https://doi.org/10.1007/s11684-021-0854-5.

[19] Subudhi PD, Rooge S, Bihari C, et al. Prolonged existence of SARS-CoV-2 RNAs in the extracellular vesicles of respiratory specimens from patients with negative reverse transcription-polymerase chain reaction. Liver Res. 2023;7: 228-236. https://doi.org/10.1016/j.livres.2023.09.004.

[20] Shi Y, Wang M, Wu L, Li X, Liao Z. COVID-19 associated liver injury: an updated review on the mechanisms and management of risk groups. Liver Res. 2023;7: 207-215. https://doi.org/10.1016/j.livres.2023.07.001.

[21] Chen L, Huang S, Yang J, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat. 2020;27:1504-1507. https://doi.org/10.1111/jvh.13362.

[22] Li Y, Li C, Wang J, et al. A case series of COVID-19 patients with chronic hep-atitis B virus infection. J Med Virol. 2020;92:2785-2791. https://doi.org/10.1002/jmv.26201.

[23] You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11:1425-1442. https://doi.org/10.14218/JCTH.2023.00320.

[24] Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020;12:e8645. https://doi.org/10.7759/cureus.8645.

[25] Yip TC, Gill M, Wong GL, Liu K.Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int. 2022;16:257-268. https://doi.org/10.1007/s12072-022-10306-x.

[26] Ou DP, Yang LY, Huang GW, Tao YM, Ding X, Chang ZG. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gas-troenterol. 2005;11:2061-2066. https://doi.org/10.3748/wjg.v11.i14.2061.

[27] Delaney WE 4th,Ray AS, Yang H, Qi X, Xiong S, Zhu Y. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477. https://doi.org/10.1128/AAC.00138-06.

[28] Jockusch S, Tao C, Li X, et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antivir Res. 2020;180:104857. https://doi.org/10.1016/j.antiviral.2020.104857.

[29] Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. https://doi.org/10.1016/j.lfs.2020.117592.

[30] Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 in-fections. World J Gastroenterol. 2021;27:782-793. https://doi.org/10.3748/wjg.v27.i9.782.

[31] Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364. https://doi.org/10.3389/fimmu.2021.733364.

[32] Wang P, Mo Z, Zhang Y, et al. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon. Front Immunol. 2023;13:1104329. https://doi.org/10.3389/fimmu.2022.1104329.

[33] Kim WR, Telep LE, Jump B, et al. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther. 2022;55: 828-835. https://doi.org/10.1111/apt.16786.

[34] Li G, Park LS, Lodi S, et al. Tenofovir disoproxil fumarate and coronavirus dis-ease 2019 outcomes in men with HIV. AIDS. 2022; 36:1689-1696. https://doi.org/10.1097/QAD.0000000000003314.

[35] Del Amo J, Polo R, Moreno S, et al. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. AIDS. 2022;36:2171-2179. https://doi.org/10.1097/QAD.0000000000003372.